Search results
Author(s):
Jozine ter Maaten
Added:
7 months ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927).
PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of…
View more
B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes
Author(s):
Torbjørn Omland
Added:
3 years ago
Article
Treatment of Acute Heart Failure - What We Have Learned to Date and How to Put it Into Practice
Author(s):
José Silva Cardoso
Added:
3 years ago
Article
Author(s):
Ali Vazir
,
Martin R Cowie
Added:
3 years ago
Acute heart failure is usually defined as the rapid onset of, or change in, signs and/or symptoms of heart failure resulting in the need for urgent treatment.1 It can occur as the first manifestation of a failing heart (acute de novo heart failure) or it can occur in a patient with a chronic history of heart failure, in which case the term ‘acute decompensation’ is often applied.
The acute heart…
View more
Author(s):
Ferenc Follath
Added:
3 years ago
Q: What are the new treatment options in acute decompensated heart failure?
A: The new treatment options are the two recently introduced drugs, the calcium sensitiser, levosimendan which has been introduced in many European countries, and a B-type natriuretic peptide (BNP) Analogon nesiritide, utilised primarily in the US. This BNP causes basal dilation and improves diuresis.
Q: How do these…
View more
Author(s):
Mikhail Kosiborod
Added:
2 years ago
In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) summarises the main findings of the EMPULSE study, originally presented as a late-breaking trial at ACC.22(NCT04157751).
The study investigated the effects of empagliflozin on symptoms,physical limitations and quality of life inacute heart failure. The trial demonstrated that treatment with empagliflozin…
View more
Jozine ter Maaten
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Kevin Damman
Research Area(s) / Expertise:
Job title: Head of the Heart Transplant and Left Ventricular Device Program
Author
Marco Metra
Research Area(s) / Expertise:
Job title: Professor
Author
Author(s):
Alexandre Mebazaa
,
Harriette Van Spall
Added:
1 year ago
AHA 22 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Alexandre Mebazaa (University Hospitals Saint Louis‐Lariboisière, FR), the primary investigator of the anticipated STRONG-HF Trial (NCT03412201).
This study aimed to evaluate the safety and efficacy of rapid-optimization heart failuretherapies. 1800 patients were randomized to receive either usual care…
View more